11 records totalling $1,468,732.01 CAD, from official Government of Canada open data.
The source files have no identifier for a recipient, and departments write the same name in different ways. This page puts together the records with these names. They differ only in letter case, accents, punctuation, "&" and "and", an article at the start, the legal form at the end (Inc., Ltd., LLP), or the French half of a name in two languages. How names are matched
| National Defence | $1,162,114 | 2 records |
| National Research Council Canada | $306,618 | 9 records |
This contract was competitively sourced.
This contract was omitted from a previous public disclosure.This contract was competitively sourced.
Development of multiple colorimetric sensors for a bandage that react to pathogenic analytes for dynamic monitoring of changes in the concentration of volatile organic compounds for identification of...
Preclinical quality, mechanical and performance testing of a hydrogel wound dressing.
Develop a regulatory strategy for a novel smart bandage to guide further product development and inform commercialization approach.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
Research and development of methodologies for packaging and manufacturing a novel medical device.
To provide employment for a recent graduate in the field of biomedical engineering in the role of technician to develop an in vitro model of wound exudate.
To provide employment for a highly qualified recent graduate in the field of market analysis and business development to assess market interest, and brand our hydrogel bandage for use in veterinary me...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.